Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19). Especially for antibody treatment and vaccine development, humora...
Saved in:
| Published in | Molecules and cells Vol. 44; no. 6; pp. 392 - 400 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Korean Society for Molecular and Cellular Biology
01.06.2021
한국분자세포생물학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1016-8478 0219-1032 0219-1032 |
| DOI | 10.14348/molcells.2021.0075 |
Cover
| Abstract | It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19). Especially for antibody treatment and vaccine development, humoral immunity to SARS-CoV-2 has been studied extensively, though there is still much that is unknown and controversial. Here, we introduce key discoveries on the humoral immune responses in COVID-19, including the immune dynamics of antibody responses and correlations with disease severity, neutralizing antibodies and their cross-reactivity, how long the antibody and memory B-cell responses last, aberrant autoreactive antibodies generated in COVID-19 patients, and the efficacy of currently available therapeutic antibodies and vaccines against circulating SARS-CoV-2 variants, and highlight gaps in the current knowledge. |
|---|---|
| AbstractList | It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19).
Especially for antibody treatment and vaccine development, humoral immunity to SARS-CoV-2 has been studied extensively, though there is still much that is unknown and controversial. Here, we introduce key discoveries on the humoral immune responses in COVID-19, including the immune dynamics of antibody responses and correlations with disease severity, neutralizing antibodies and their cross-reactivity, how long the antibody and memory B-cell responses last, aberrant autoreactive antibodies generated in COVID-19 patients, and the efficacy of currently available therapeutic antibodies and vaccines against circulating SARSCoV- 2 variants, and highlight gaps in the current knowledge. KCI Citation Count: 19 It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19). Especially for antibody treatment and vaccine development, humoral immunity to SARS-CoV-2 has been studied extensively, though there is still much that is unknown and controversial. Here, we introduce key discoveries on the humoral immune responses in COVID-19, including the immune dynamics of antibody responses and correlations with disease severity, neutralizing antibodies and their cross-reactivity, how long the antibody and memory B-cell responses last, aberrant autoreactive antibodies generated in COVID-19 patients, and the efficacy of currently available therapeutic antibodies and vaccines against circulating SARS-CoV-2 variants, and highlight gaps in the current knowledge. |
| Author | Oh, Ji Eun Lee, Eunjin |
| AuthorAffiliation | 2 BioMedical Research Center, KAIST, Daejeon 34141, Korea 1 Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea |
| AuthorAffiliation_xml | – name: 2 BioMedical Research Center, KAIST, Daejeon 34141, Korea – name: 1 Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea |
| Author_xml | – sequence: 1 givenname: Eunjin orcidid: 0000-0001-7659-9951 surname: Lee fullname: Lee, Eunjin – sequence: 2 givenname: Ji Eun orcidid: 0000-0003-2511-7064 surname: Oh fullname: Oh, Ji Eun |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34059562$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002729778$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNqNkMtKAzEUhoMoWi9PIMhsXUzNZZKZbIRSb0VBadVtyGQybXQmKZNU6dubWhV1Ia5OIP93zs-3CzatsxqAQwT7KCNZcdK6Rumm8X0MMepDmNMN0ItPniJI8CboIYhYWmR5sQN2vX-CEOUMF9tgh2SQcspwD1xfLVrXySYZte3CmrBM5FQa60MyGYwn6dA9pjiRtkrCTMfMXKqQOJsMbx9HZyniyZ0MMzfVVnvj98FWLRuvDz7mHni4OL8fXqU3t5ej4eAmVRnhIUWIlbSMdSFmFKGKSaV0pVkltcR5mVMOGakJ5QzWCpdUFzSvc8xklWmFc0j2wPF6r-1q8ayMcNK8z6kTz50YjO9HgnNMGKIxm62zCzuXy1fZNGLemVZ2S4GgePcoPj2KlUex8hix0zU2X5StrpS2IUr6QlcHf_5YM4vnX0SBM0oQiwuOvi_4Ij_NxwBZB1TnvO90_c9e_BelTJDBuFUL0_zJvgHAEquT |
| CitedBy_id | crossref_primary_10_1007_s00011_022_01596_w crossref_primary_10_1055_s_0042_1748170 crossref_primary_10_1016_j_apsb_2023_08_023 crossref_primary_10_3389_fimmu_2022_864278 crossref_primary_10_1002_jmv_29529 crossref_primary_10_1016_j_ijid_2022_12_009 crossref_primary_10_1016_j_jiac_2022_03_002 crossref_primary_10_3389_fimmu_2022_835104 crossref_primary_10_14348_molcells_2021_0146 crossref_primary_10_3389_fimmu_2022_1001198 crossref_primary_10_14348_molcells_2023_2170 crossref_primary_10_3390_children11060736 crossref_primary_10_3390_v14092039 crossref_primary_10_15789_2220_7619_TMM_8878 crossref_primary_10_3389_fcimb_2022_931061 crossref_primary_10_1038_s41598_022_06038_5 crossref_primary_10_1007_s00005_023_00673_0 crossref_primary_10_1016_j_jcv_2022_105292 crossref_primary_10_37349_ei_2023_00101 crossref_primary_10_3897_pharmacia_69_e81063 |
| Cites_doi | 10.1136/bmj.n296 10.1001/jama.2021.1612 10.1126/science.abg6105 10.1038/s41586-021-03412-7 10.1126/scitranslmed.abd2223 10.1038/s41586-020-2538-8 10.1056/NEJMoa2034201 10.1126/science.abd0831 10.1001/jama.2021.0202 10.1038/s41564-020-00824-5 10.1056/NEJMoa2029849 10.1056/NEJMe2108162 10.1038/s41586-020-2381-y 10.1016/j.cell.2020.11.029 10.1038/s41541-021-00313-8 10.1126/science.abd7728 10.1126/sciimmunol.abe0240 10.1016/j.cell.2020.05.025 10.1126/sciimmunol.abf8891 10.1056/NEJMoa2034577 10.1126/science.abe5901 10.1016/j.cell.2021.02.010 10.1056/NEJMc2025179 10.1080/22221751.2020.1729069 10.1093/cid/ciaa344 10.3201/eid2704.210138 10.1016/j.cell.2020.06.043 10.1016/j.cell.2020.07.012 10.1056/NEJMoa2035389 10.1038/s41591-021-01270-4 10.1016/j.cell.2020.12.015 10.3201/eid2705.210191 10.1038/s41586-021-03207-w 10.1038/s41586-021-03324-6 10.1016/j.immuni.2020.07.020 10.1038/s41586-020-2349-y 10.3390/v12121414 10.1016/j.cell.2020.10.052 10.1016/S1473-3099(20)30943-9 10.1038/s41591-021-01265-1 10.1038/s41591-021-01255-3 10.1038/s41591-021-01285-x 10.1038/s41586-020-2571-7 10.15585/mmwr.mm7003e2 10.1016/S0140-6736(20)32661-1 10.1016/j.tmaid.2021.102023 10.3201/eid2703.210038 10.1126/sciadv.abc9999 10.3390/v12121390 10.1038/s41590-020-00814-z 10.1016/j.cell.2021.03.036 10.1126/scitranslmed.abf1555 10.1016/j.cell.2021.01.050 10.1016/j.cell.2021.04.006 10.1016/j.jinf.2021.03.013 10.1126/science.abc5902 10.1126/science.abe1107 10.1172/jci.insight.123158 10.1056/NEJMoa2026116 10.1001/jamapediatrics.2020.1467 10.1038/s41586-020-2380-z 10.1038/s41586-020-2852-1 10.1126/science.abd4585 10.1016/j.chom.2020.11.007 10.1126/science.abf9302 10.1038/s41564-020-00813-8 10.1126/science.abe2402 10.1016/j.chom.2020.11.012 10.1038/s41586-020-2548-6 |
| ContentType | Journal Article |
| Copyright | The Korean Society for Molecular and Cellular Biology. All rights reserved. 2021 |
| Copyright_xml | – notice: The Korean Society for Molecular and Cellular Biology. All rights reserved. 2021 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 5PM ADTOC UNPAY ACYCR |
| DOI | 10.14348/molcells.2021.0075 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 0219-1032 |
| EndPage | 400 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_9923615 10.14348/molcells.2021.0075 PMC8245316 34059562 10_14348_molcells_2021_0075 |
| Genre | Journal Article Review |
| GroupedDBID | --- 0R~ 0VY 123 1N0 29M 2VQ 2WC 30V 4.4 408 40D 53G 5VS 67N 67Z 7X7 88E 8AO 8FE 8FH 8FI 8FJ 8TC 8UJ 95. 9ZL AALRI AARHV AAXUO AAYWO AAYXX ABFSG ABMNI ABUWG ACBXY ACGFO ACGFS ACPRK ACREN ACSTC ACVFH ADBBV ADCNI ADKPE ADVLN AENEX AEUPX AEZWR AFGCZ AFHIU AFJKZ AFKRA AFLOW AFPUW AGJBK AHBYD AHMBA AHSBF AHWEU AIGII AITUG AIXLP AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMKLP AMRAJ AMTXH AOIJS APXCP ASPBG AVWKF AZFZN BBNVY BENPR BGNMA BHPHI BPHCQ BVBZV BVXVI CAG CCPQU CITATION COF CS3 CSCUP DU5 E3Z EBS EJD F5P FDB FYUFA GROUPED_DOAJ GX1 H13 HCIFZ HF~ HG6 HH5 HMCUK HMJXF HYE HZ~ I09 I0C IXC I~X JDI KDC KOV KVFHK LAS LK8 M1P M41 M4Y M7P MA- NU0 OK1 P2P PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q2X R9I ROL RPM RSV S1Z S27 S3A S3B SBL SDH SJN SOJ T13 TSK U2A UKHRP VC2 WK8 Z45 ~A9 .UV CGR CUY CVF ECM EIF NPM 5PM ADTOC UNPAY 3V. 88A ABDBF ABJNI ABTEG ACYCR ADINQ AFNRJ EAD EAP EBC EBD EMK EMOBN EST ESX M0L SV3 TUS |
| ID | FETCH-LOGICAL-c439t-116b5b007026511d6accede6daea27b759063f35960fc2b5e857f726ad4ec2703 |
| IEDL.DBID | UNPAY |
| ISSN | 1016-8478 0219-1032 |
| IngestDate | Fri Apr 19 03:47:28 EDT 2024 Sun Oct 26 03:57:06 EDT 2025 Tue Sep 30 15:40:33 EDT 2025 Mon Jul 21 05:56:55 EDT 2025 Sat Oct 25 05:18:24 EDT 2025 Thu Apr 24 22:56:55 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | COVID-19 SARS-CoV-2 variants neutralizing antibody SARS-CoV-2 humoral immunity |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 cc-by-nc-sa |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c439t-116b5b007026511d6accede6daea27b759063f35960fc2b5e857f726ad4ec2703 |
| ORCID | 0000-0001-7659-9951 0000-0003-2511-7064 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.molcells.org/journal/download_pdf.php?doi=10.14348/molcells.2021.0075 |
| PMID | 34059562 |
| PageCount | 9 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9923615 unpaywall_primary_10_14348_molcells_2021_0075 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8245316 pubmed_primary_34059562 crossref_primary_10_14348_molcells_2021_0075 crossref_citationtrail_10_14348_molcells_2021_0075 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-06-01 |
| PublicationDateYYYYMMDD | 2021-06-01 |
| PublicationDate_xml | – month: 06 year: 2021 text: 2021-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Molecules and cells |
| PublicationTitleAlternate | Mol Cells |
| PublicationYear | 2021 |
| Publisher | Korean Society for Molecular and Cellular Biology 한국분자세포생물학회 |
| Publisher_xml | – name: Korean Society for Molecular and Cellular Biology – name: 한국분자세포생물학회 |
| References | Sadoff (10.14348/molcells.2021.0075_bib61) 2021 Wang (10.14348/molcells.2021.0075_bib74) 2021; 13 Collier (10.14348/molcells.2021.0075_bib17) 2021 Woodruff (10.14348/molcells.2021.0075_bib78) 2020 Castagnoli (10.14348/molcells.2021.0075_bib14) 2020; 174 Hashem (10.14348/molcells.2021.0075_bib31) 2020; 12 Hoffmann (10.14348/molcells.2021.0075_bib34) 2021 Wajnberg (10.14348/molcells.2021.0075_bib72) 2020; 370 Atyeo (10.14348/molcells.2021.0075_bib5) 2020; 53 Poston (10.14348/molcells.2021.0075_bib54) 2020 (10.14348/molcells.2021.0075_bib1) 2020; 62 Santos (10.14348/molcells.2021.0075_bib60) 2020 Rubin (10.14348/molcells.2021.0075_bib59) 2021; 384 Garcia-Beltran (10.14348/molcells.2021.0075_bib24) 2021; 184 Starr (10.14348/molcells.2021.0075_bib66) 2021; 371 Roltgen (10.14348/molcells.2021.0075_bib57) 2020; 5 Zhu (10.14348/molcells.2021.0075_bib86) 2020; 6 Liu (10.14348/molcells.2021.0075_bib41) 2019; 4 Arvin (10.14348/molcells.2021.0075_bib4) 2020; 584 Baden (10.14348/molcells.2021.0075_bib6) 2021; 384 Oude Munnink (10.14348/molcells.2021.0075_bib49) 2021; 371 Lucas (10.14348/molcells.2021.0075_bib42) 2020 Korber (10.14348/molcells.2021.0075_bib37) 2020; 182 Zhao (10.14348/molcells.2021.0075_bib85) 2020; 71 Zuniga (10.14348/molcells.2021.0075_bib90) 2021 Weissman (10.14348/molcells.2021.0075_bib76) 2021; 29 Brouwer (10.14348/molcells.2021.0075_bib12) 2020; 369 Gudbjartsson (10.14348/molcells.2021.0075_bib28) 2020; 383 Wang (10.14348/molcells.2021.0075_bib73) 2020 Bhadelia (10.14348/molcells.2021.0075_bib11) 2021 Zhang (10.14348/molcells.2021.0075_bib84) 2021; 325 Liu (10.14348/molcells.2021.0075_bib39) 2021 Rodda (10.14348/molcells.2021.0075_bib56) 2021; 184 Greaney (10.14348/molcells.2021.0075_bib27) 2021; 29 Sokal (10.14348/molcells.2021.0075_bib64) 2021; 184 Ju (10.14348/molcells.2021.0075_bib36) 2020; 584 Muik (10.14348/molcells.2021.0075_bib44) 2021; 371 Deng (10.14348/molcells.2021.0075_bib18) 2021 10.14348/molcells.2021.0075_bib50 Barnes (10.14348/molcells.2021.0075_bib7) 2020; 588 Galloway (10.14348/molcells.2021.0075_bib23) 2021; 70 Polack (10.14348/molcells.2021.0075_bib53) 2020; 383 Anderson (10.14348/molcells.2021.0075_bib2) 2021; 184 Happi (10.14348/molcells.2021.0075_bib29) 2021; 27 Pinto (10.14348/molcells.2021.0075_bib52) 2020; 583 Ibarrondo (10.14348/molcells.2021.0075_bib35) 2020; 383 Yadav (10.14348/molcells.2021.0075_bib82) 2021; 41 Roltgen (10.14348/molcells.2021.0075_bib58) 2020 Xie (10.14348/molcells.2021.0075_bib81) 2021; 27 Mahase (10.14348/molcells.2021.0075_bib43) 2021; 372 Seow (10.14348/molcells.2021.0075_bib62) 2020; 5 Gottlieb (10.14348/molcells.2021.0075_bib26) 2021; 325 Hirotsu (10.14348/molcells.2021.0075_bib33) 2021; 82 Baum (10.14348/molcells.2021.0075_bib9) 2020; 370 Nonaka (10.14348/molcells.2021.0075_bib48) 2021; 27 Fujino (10.14348/molcells.2021.0075_bib21) 2021; 27 Li (10.14348/molcells.2021.0075_bib38) 2020; 182 Shi (10.14348/molcells.2021.0075_bib63) 2020; 584 Tian (10.14348/molcells.2021.0075_bib70) 2020; 9 Sterlin (10.14348/molcells.2021.0075_bib67) 2021; 13 Faria (10.14348/molcells.2021.0075_bib20) 2021 Hartley (10.14348/molcells.2021.0075_bib30) 2020; 5 Bastard (10.14348/molcells.2021.0075_bib8) 2020; 370 Cao (10.14348/molcells.2021.0075_bib13) 2020; 182 Zhang (10.14348/molcells.2021.0075_bib83) 2021; 6 Gaebler (10.14348/molcells.2021.0075_bib22) 2021; 591 Tegally (10.14348/molcells.2021.0075_bib69) 2021; 27 Chen (10.14348/molcells.2021.0075_bib15) 2021; 384 Wu (10.14348/molcells.2021.0075_bib80) 2021 Garcia-Beltran (10.14348/molcells.2021.0075_bib25) 2021 Nguyen-Contant (10.14348/molcells.2021.0075_bib47) 2020; 11 Woodruff (10.14348/molcells.2021.0075_bib79) 2020; 21 Heath (10.14348/molcells.2021.0075_bib32) 2021 Zou (10.14348/molcells.2021.0075_bib89) 2021; 6 Paiva (10.14348/molcells.2021.0075_bib51) 2020; 12 Song (10.14348/molcells.2021.0075_bib65) 2020 Liu (10.14348/molcells.2021.0075_bib40) 2020; 584 Tan (10.14348/molcells.2021.0075_bib68) 2020 Zost (10.14348/molcells.2021.0075_bib88) 2020; 584 Resende (10.14348/molcells.2021.0075_bib55) 2021 Zohar (10.14348/molcells.2021.0075_bib87) 2020; 183 Baum (10.14348/molcells.2021.0075_bib10) 2020; 369 Claro (10.14348/molcells.2021.0075_bib16) 2021; 27 Wibmer (10.14348/molcells.2021.0075_bib77) 2021; 27 Ng (10.14348/molcells.2021.0075_bib46) 2020; 370 Voysey (10.14348/molcells.2021.0075_bib71) 2021; 397 Annavajhala (10.14348/molcells.2021.0075_bib3) 2021 Duysburgh (10.14348/molcells.2021.0075_bib19) 2021; 21 Wang (10.14348/molcells.2021.0075_bib75) 2021; 592 Naveca (10.14348/molcells.2021.0075_bib45) 2021 |
| References_xml | – volume: 372 start-page: n296 year: 2021 ident: 10.14348/molcells.2021.0075_bib43 article-title: Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant publication-title: BMJ doi: 10.1136/bmj.n296 – volume: 325 start-page: 1324 year: 2021 ident: 10.14348/molcells.2021.0075_bib84 article-title: Emergence of a novel SARS-CoV-2 variant in Southern California publication-title: JAMA doi: 10.1001/jama.2021.1612 – volume: 371 start-page: 1152 year: 2021 ident: 10.14348/molcells.2021.0075_bib44 article-title: Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera publication-title: Science doi: 10.1126/science.abg6105 – year: 2021 ident: 10.14348/molcells.2021.0075_bib3 article-title: A novel SARS-CoV-2 variant of concern, B. 1.526, identified in New York publication-title: MedRxiv – year: 2021 ident: 10.14348/molcells.2021.0075_bib17 article-title: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies publication-title: Nature doi: 10.1038/s41586-021-03412-7 – volume: 13 start-page: eabd2223 year: 2021 ident: 10.14348/molcells.2021.0075_bib67 article-title: IgA dominates the early neutralizing antibody response to SARS-CoV-2 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abd2223 – volume: 584 start-page: 353 year: 2020 ident: 10.14348/molcells.2021.0075_bib4 article-title: A perspective on potential antibody-dependent enhancement of SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-020-2538-8 – year: 2020 ident: 10.14348/molcells.2021.0075_bib60 article-title: The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation publication-title: BioRxiv – year: 2021 ident: 10.14348/molcells.2021.0075_bib61 article-title: Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2034201 – volume: 369 start-page: 1014 year: 2020 ident: 10.14348/molcells.2021.0075_bib10 article-title: Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies publication-title: Science doi: 10.1126/science.abd0831 – volume: 325 start-page: 632 year: 2021 ident: 10.14348/molcells.2021.0075_bib26 article-title: Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2021.0202 – volume: 6 start-page: 51 year: 2021 ident: 10.14348/molcells.2021.0075_bib83 article-title: Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals publication-title: Nat. Microbiol. doi: 10.1038/s41564-020-00824-5 – volume: 384 start-page: 229 year: 2021 ident: 10.14348/molcells.2021.0075_bib15 article-title: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2029849 – volume: 384 start-page: e14 year: 2021 ident: 10.14348/molcells.2021.0075_bib59 article-title: Audio interview: Covid-19 in South Africa and a new SARS-CoV-2 variant publication-title: N. Engl. J. Med. doi: 10.1056/NEJMe2108162 – volume: 584 start-page: 120 year: 2020 ident: 10.14348/molcells.2021.0075_bib63 article-title: A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-020-2381-y – volume: 184 start-page: 169 year: 2021 ident: 10.14348/molcells.2021.0075_bib56 article-title: Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 publication-title: Cell doi: 10.1016/j.cell.2020.11.029 – volume: 6 start-page: 44 year: 2021 ident: 10.14348/molcells.2021.0075_bib89 article-title: The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization publication-title: NPJ Vaccines doi: 10.1038/s41541-021-00313-8 – volume: 370 start-page: 1227 year: 2020 ident: 10.14348/molcells.2021.0075_bib72 article-title: Robust neutralizing antibodies to SARS-CoV-2 infection persist for months publication-title: Science doi: 10.1126/science.abd7728 – volume: 5 start-page: eabe0240 year: 2020 ident: 10.14348/molcells.2021.0075_bib57 article-title: Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abe0240 – volume: 182 start-page: 73 year: 2020 ident: 10.14348/molcells.2021.0075_bib13 article-title: Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells publication-title: Cell doi: 10.1016/j.cell.2020.05.025 – volume: 5 start-page: eabf8891 year: 2020 ident: 10.14348/molcells.2021.0075_bib30 article-title: Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abf8891 – volume: 383 start-page: 2603 year: 2020 ident: 10.14348/molcells.2021.0075_bib53 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2034577 – volume: 371 start-page: 172 year: 2021 ident: 10.14348/molcells.2021.0075_bib49 article-title: Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans publication-title: Science doi: 10.1126/science.abe5901 – volume: 184 start-page: 1858 year: 2021 ident: 10.14348/molcells.2021.0075_bib2 article-title: Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection publication-title: Cell doi: 10.1016/j.cell.2021.02.010 – volume: 383 start-page: 1085 year: 2020 ident: 10.14348/molcells.2021.0075_bib35 article-title: Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2025179 – volume: 9 start-page: 382 year: 2020 ident: 10.14348/molcells.2021.0075_bib70 article-title: Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody publication-title: Emerg. Microbes Infect. doi: 10.1080/22221751.2020.1729069 – year: 2020 ident: 10.14348/molcells.2021.0075_bib58 article-title: SARS-CoV-2 antibody responses correlate with resolution of RNAemia but are short-lived in patients with mild illness publication-title: MedRxiv – year: 2020 ident: 10.14348/molcells.2021.0075_bib78 article-title: Clinically identifiable autoreactivity is common in severe SARS-CoV-2 Infection publication-title: MedRxiv – year: 2020 ident: 10.14348/molcells.2021.0075_bib54 article-title: Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection publication-title: Clin. Infect. Dis – volume: 71 start-page: 2027 year: 2020 ident: 10.14348/molcells.2021.0075_bib85 article-title: Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa344 – volume: 27 start-page: 1243 year: 2021 ident: 10.14348/molcells.2021.0075_bib21 article-title: Novel SARS-CoV-2 variant in travelers from Brazil to Japan publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2704.210138 – volume: 182 start-page: 812 year: 2020 ident: 10.14348/molcells.2021.0075_bib37 article-title: Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus publication-title: Cell doi: 10.1016/j.cell.2020.06.043 – volume: 182 start-page: 1284 year: 2020 ident: 10.14348/molcells.2021.0075_bib38 article-title: The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity publication-title: Cell doi: 10.1016/j.cell.2020.07.012 – volume: 384 start-page: 403 year: 2021 ident: 10.14348/molcells.2021.0075_bib6 article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2035389 – volume: 27 start-page: 620 year: 2021 ident: 10.14348/molcells.2021.0075_bib81 article-title: Neutralization of SARS- CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera publication-title: Nat. Med. doi: 10.1038/s41591-021-01270-4 – volume: 184 start-page: 476 year: 2021 ident: 10.14348/molcells.2021.0075_bib24 article-title: COVID-19-neutralizing antibodies predict disease severity and survival publication-title: Cell doi: 10.1016/j.cell.2020.12.015 – volume: 27 start-page: 1522 year: 2021 ident: 10.14348/molcells.2021.0075_bib48 article-title: Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2705.210191 – year: 2021 ident: 10.14348/molcells.2021.0075_bib18 article-title: Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation publication-title: MedRxiv – ident: 10.14348/molcells.2021.0075_bib50 – volume: 591 start-page: 639 year: 2021 ident: 10.14348/molcells.2021.0075_bib22 article-title: Evolution of antibody immunity to SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-021-03207-w – year: 2021 ident: 10.14348/molcells.2021.0075_bib39 article-title: 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro publication-title: BioRxiv – volume: 592 start-page: 616 year: 2021 ident: 10.14348/molcells.2021.0075_bib75 article-title: mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants publication-title: Nature doi: 10.1038/s41586-021-03324-6 – year: 2021 ident: 10.14348/molcells.2021.0075_bib11 article-title: Distinct autoimmune antibody signatures between hospitalized acute COVID-19 patients, SARS-CoV-2 convalescent individuals, and unexposed pre-pandemic controls publication-title: MedRxiv – volume: 53 start-page: 524 year: 2020 ident: 10.14348/molcells.2021.0075_bib5 article-title: Distinct early serological signatures track with SARS-CoV-2 survival publication-title: Immunity doi: 10.1016/j.immuni.2020.07.020 – volume: 583 start-page: 290 year: 2020 ident: 10.14348/molcells.2021.0075_bib52 article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody publication-title: Nature doi: 10.1038/s41586-020-2349-y – volume: 12 start-page: 1414 year: 2020 ident: 10.14348/molcells.2021.0075_bib51 article-title: Multiple introductions followed by ongoing community spread of SARS-CoV-2 at one of the largest metropolitan areas of Northeast Brazil publication-title: Viruses doi: 10.3390/v12121414 – volume: 183 start-page: 1508 year: 2020 ident: 10.14348/molcells.2021.0075_bib87 article-title: Compromised humoral functional evolution tracks with SARS-CoV-2 mortality publication-title: Cell doi: 10.1016/j.cell.2020.10.052 – volume: 21 start-page: 163 year: 2021 ident: 10.14348/molcells.2021.0075_bib19 article-title: Persistence of IgG response to SARS-CoV-2 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30943-9 – year: 2021 ident: 10.14348/molcells.2021.0075_bib45 article-title: SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P.1 in Amazonas, Brazil publication-title: virological – volume: 27 start-page: 372 year: 2021 ident: 10.14348/molcells.2021.0075_bib29 article-title: Tracking the emergence of new SARS-CoV-2 variants in South Africa publication-title: Nat. Med. doi: 10.1038/s41591-021-01265-1 – volume: 27 start-page: 440 year: 2021 ident: 10.14348/molcells.2021.0075_bib69 article-title: Sixteen novel lineages of SARS-CoV-2 in South Africa publication-title: Nat. Med. doi: 10.1038/s41591-021-01255-3 – year: 2020 ident: 10.14348/molcells.2021.0075_bib68 article-title: Viral kinetics and antibody responses in patients with COVID-19 publication-title: MedRxiv – volume: 27 start-page: 622 year: 2021 ident: 10.14348/molcells.2021.0075_bib77 article-title: SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma publication-title: Nat. Med. doi: 10.1038/s41591-021-01285-x – volume: 584 start-page: 450 year: 2020 ident: 10.14348/molcells.2021.0075_bib40 article-title: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike publication-title: Nature doi: 10.1038/s41586-020-2571-7 – volume: 70 start-page: 95 year: 2021 ident: 10.14348/molcells.2021.0075_bib23 article-title: Emergence of SARS-CoV-2 B.1.1.7 lineage - United States, December 29, 2020-January 12, 2021 publication-title: MMWR Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm7003e2 – volume: 397 start-page: 99 year: 2021 ident: 10.14348/molcells.2021.0075_bib71 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet doi: 10.1016/S0140-6736(20)32661-1 – volume: 41 year: 2021 ident: 10.14348/molcells.2021.0075_bib82 article-title: Imported SARS-CoV-2 V501Y. V2 variant (B. 1.351) detected in travelers from South Africa and Tanzania to India publication-title: Travel Med. Infect. Dis. doi: 10.1016/j.tmaid.2021.102023 – volume: 27 start-page: 970 year: 2021 ident: 10.14348/molcells.2021.0075_bib16 article-title: Local transmission of SARS-CoV-2 lineage B.1.1.7, Brazil, December 2020 publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2703.210038 – volume: 6 start-page: eabc9999 year: 2020 ident: 10.14348/molcells.2021.0075_bib86 article-title: Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals publication-title: Sci. Adv. doi: 10.1126/sciadv.abc9999 – volume: 12 start-page: 1390 year: 2020 ident: 10.14348/molcells.2021.0075_bib31 article-title: Early humoral response correlates with disease severity and outcomes in COVID-19 patients publication-title: Viruses doi: 10.3390/v12121390 – volume: 11 start-page: e01991 year: 2020 ident: 10.14348/molcells.2021.0075_bib47 article-title: S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit publication-title: Bio – volume: 21 start-page: 1506 year: 2020 ident: 10.14348/molcells.2021.0075_bib79 article-title: Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19 publication-title: Nat. Immunol. doi: 10.1038/s41590-020-00814-z – year: 2021 ident: 10.14348/molcells.2021.0075_bib34 article-title: SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies publication-title: Cell doi: 10.1016/j.cell.2021.03.036 – year: 2021 ident: 10.14348/molcells.2021.0075_bib32 article-title: Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1. 7 variant publication-title: MedRxiv – year: 2021 ident: 10.14348/molcells.2021.0075_bib90 article-title: Autoimmunity to the lung protective phospholipid-binding protein Annexin A2 predicts mortality among hospitalized COVID-19 patients publication-title: MedRxiv – volume: 13 start-page: eabf1555 year: 2021 ident: 10.14348/molcells.2021.0075_bib74 article-title: Enhanced SARS-CoV-2 neutralization by dimeric IgA publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abf1555 – year: 2020 ident: 10.14348/molcells.2021.0075_bib42 article-title: Kinetics of antibody responses dictate COVID-19 outcome publication-title: MedRxiv – volume: 184 start-page: 1201 year: 2021 ident: 10.14348/molcells.2021.0075_bib64 article-title: Maturation and persistence of the anti-SARS-CoV-2 memory B cell response publication-title: Cell doi: 10.1016/j.cell.2021.01.050 – year: 2021 ident: 10.14348/molcells.2021.0075_bib20 article-title: Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil publication-title: MedRxiv – year: 2021 ident: 10.14348/molcells.2021.0075_bib25 article-title: Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity publication-title: Cell doi: 10.1016/j.cell.2021.04.006 – volume: 82 start-page: 276 year: 2021 ident: 10.14348/molcells.2021.0075_bib33 article-title: Discovery of a SARS-CoV-2 variant from the P. 1 lineage harboring K417T/E484K/N501Y mutations in Kofu, Japan publication-title: J. Infect doi: 10.1016/j.jinf.2021.03.013 – year: 2021 ident: 10.14348/molcells.2021.0075_bib55 article-title: Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil, 2020 publication-title: virological – year: 2020 ident: 10.14348/molcells.2021.0075_bib73 article-title: Diverse functional autoantibodies in patients with COVID-19 publication-title: MedRxiv – volume: 369 start-page: 643 year: 2020 ident: 10.14348/molcells.2021.0075_bib12 article-title: Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability publication-title: Science doi: 10.1126/science.abc5902 – volume: 370 start-page: 1339 year: 2020 ident: 10.14348/molcells.2021.0075_bib46 article-title: Preexisting and de novo humoral immunity to SARS-CoV-2 in humans publication-title: Science doi: 10.1126/science.abe1107 – volume: 4 start-page: e123158 year: 2019 ident: 10.14348/molcells.2021.0075_bib41 article-title: Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection publication-title: JCI Insight doi: 10.1172/jci.insight.123158 – volume: 383 start-page: 1724 year: 2020 ident: 10.14348/molcells.2021.0075_bib28 article-title: Humoral immune response to SARS-CoV-2 in Iceland publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2026116 – volume: 174 start-page: 882 year: 2020 ident: 10.14348/molcells.2021.0075_bib14 article-title: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review publication-title: JAMA Pediatr. doi: 10.1001/jamapediatrics.2020.1467 – volume: 584 start-page: 115 year: 2020 ident: 10.14348/molcells.2021.0075_bib36 article-title: Human neutralizing antibodies elicited by SARS-CoV-2 infection publication-title: Nature doi: 10.1038/s41586-020-2380-z – volume: 588 start-page: 682 year: 2020 ident: 10.14348/molcells.2021.0075_bib7 article-title: SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies publication-title: Nature doi: 10.1038/s41586-020-2852-1 – year: 2020 ident: 10.14348/molcells.2021.0075_bib65 article-title: Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection publication-title: BioRxiv – volume: 62 start-page: 185 year: 2020 ident: 10.14348/molcells.2021.0075_bib1 article-title: An EUA for bamlanivimab - a monoclonal antibody for COVID-19 publication-title: Med. Lett. Drugs Ther. – volume: 370 start-page: eabd4585 year: 2020 ident: 10.14348/molcells.2021.0075_bib8 article-title: Autoantibodies against type I IFNs in patients with life-threatening COVID-19 publication-title: Science doi: 10.1126/science.abd4585 – volume: 29 start-page: 44 year: 2021 ident: 10.14348/molcells.2021.0075_bib27 article-title: Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition publication-title: Cell Host Microbe doi: 10.1016/j.chom.2020.11.007 – volume: 371 start-page: 850 year: 2021 ident: 10.14348/molcells.2021.0075_bib66 article-title: Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 publication-title: Science doi: 10.1126/science.abf9302 – year: 2021 ident: 10.14348/molcells.2021.0075_bib80 article-title: mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants publication-title: BioRxiv – volume: 5 start-page: 1598 year: 2020 ident: 10.14348/molcells.2021.0075_bib62 article-title: Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans publication-title: Nat. Microbiol. doi: 10.1038/s41564-020-00813-8 – volume: 370 start-page: 1110 year: 2020 ident: 10.14348/molcells.2021.0075_bib9 article-title: REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters publication-title: Science doi: 10.1126/science.abe2402 – volume: 29 start-page: 23 year: 2021 ident: 10.14348/molcells.2021.0075_bib76 article-title: D614G spike mutation increases SARS CoV-2 susceptibility to neutralization publication-title: Cell Host Microbe doi: 10.1016/j.chom.2020.11.012 – volume: 584 start-page: 443 year: 2020 ident: 10.14348/molcells.2021.0075_bib88 article-title: Potently neutralizing and protective human antibodies against SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-020-2548-6 |
| SSID | ssj0017628 ssib049006238 ssib053376808 |
| Score | 2.4020536 |
| SecondaryResourceType | review_article |
| Snippet | It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the... |
| SourceID | nrf unpaywall pubmedcentral pubmed crossref |
| SourceType | Open Website Open Access Repository Index Database Enrichment Source |
| StartPage | 392 |
| SubjectTerms | Antibodies, Neutralizing - biosynthesis Antibodies, Neutralizing - therapeutic use Antibodies, Viral - biosynthesis Antibody-Dependent Enhancement Autoantibodies - biosynthesis B-Lymphocytes - immunology B-Lymphocytes - virology COVID-19 - immunology COVID-19 - mortality COVID-19 - virology COVID-19 Drug Treatment Host-Pathogen Interactions - immunology Humans Immunity, Humoral - drug effects Immunoglobulin A - biosynthesis Immunoglobulin Class Switching Immunoglobulin G - biosynthesis Immunoglobulin M - biosynthesis Immunologic Memory Minireview SARS-CoV-2 - immunology SARS-CoV-2 - pathogenicity Severity of Illness Index Survival Analysis 생물학 |
| Title | Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34059562 https://pubmed.ncbi.nlm.nih.gov/PMC8245316 https://www.molcells.org/journal/download_pdf.php?doi=10.14348/molcells.2021.0075 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002729778 |
| UnpaywallVersion | publishedVersion |
| Volume | 44 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Molecules and Cells, 2021, 44(6), , pp.392-400 |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 0219-1032 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017628 issn: 1016-8478 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 0219-1032 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017628 issn: 1016-8478 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 0219-1032 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017628 issn: 1016-8478 databaseCode: AKRWK dateStart: 19901001 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAQN databaseName: PubMed Central (Free e-resource, activated by CARLI) customDbUrl: eissn: 0219-1032 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017628 issn: 1016-8478 databaseCode: RPM dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 0219-1032 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017628 issn: 1016-8478 databaseCode: U2A dateStart: 20000201 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELe2TghexuegfMlCPOItdmIneeChKkwraKUwOo0ny4mdUrVLqi4VKn89d0karZNAIPHiRMrZis9n3-_88TMhrzn3o8S3GQP3EbIg45xFwkYsVV5gjMedk3je-XSoTsbBhwt5sUM-b87C4LbKy2KOs9ZX1UJ-o9Iji9zxhbF6YbOKOAK6_Fvs8oEfREdtFojlOdJhy12ypyTA8w7ZGw9HvW_VXAuPGRLIVSugXDEYmaOGieg3pWx5q918mV1zVDc3Ud5e5Quz_mHm82se6vguWW7qVm9MmR2uyuQw_XmD9vG_Vv4e2W_wLO3VBnif7Lj8AblV33C5fkg-grkgBwAdVOdQyjU1EzMFSErPel_OWL84Z4Ka3FLAoSCDJzZpkdP-p_PBO8ZjOgKAWkxwPJ5ePSLj4_df-yesub-BpQBzSsa5SmSChEJCAa6zyqSps05Z44wIk1DGgI8yH1spS0UiXSTDLBTK2MClAoaiA9LJi9w9IVQ6aTwL_ja0fuCkTDLllHGeg5KkzLwuEZt20mlDbo53bMw1BjmoJb3RkkYtadRSl7xpMy1qbo8_i78CA9CzdKqRkxufk0LPlhoij4GOY6SxAaHHtVm0JfoAiSEIFV0SbhlMK4CFbX_Jp98rou9IBDBEqi5hrWn9zY8-_Uf5Z-QOvtcb4J6TTrlcuRcAtcrkZTVFAelwdArpWMB73Z1-ATypKiU |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELe2Tghe-P4oX7IQj3iLndhJHnioCtMKYgxGp_FkObFdqpak6lKh8tdzl6TROgkEEk-JlPMpPp99P3_cz4S85DxMstB6BuEjZpHnnCXCJixXQWRMwJ2TmO_84VgdjaN35_J8h3za5MLgscrv5RxXrS_qjfzWpAcWueNLY_XC-po4Arr8a-zyURglB10RmMtzpMOWu2RPSYDnPbI3Pj4ZfK3XWnjKkECu3gHlisHInLRMRL_RshWtdoulvxSorh6ivL4qFmb9w8znlyLU4S2y3NStOZgy219V2X7-8wrt43-t_G1ys8WzdNA44B2y44q75Fpzw-X6HnkP7oIcAHRU56FUa2omZgqQlJ4OPp-yYXnGBDWFpYBDQQYzNmlZ0OHHs9EbxlN6AgC1nOB4PL24T8aHb78Mj1h7fwPLAeZUjHOVyQwJhYQCXGeVyXNnnbLGGRFnsUwBH_kQW8nnIpMukbGPhTI2crmAoegB6RVl4R4RKp00gYV4G9swclJmXjllXOBAk5Q-6BOxaSedt-TmeMfGXOMkB62kN1bSaCWNVuqTV12hRcPt8WfxF-AAepZPNXJy43NS6tlSw8xjpNMUaWxA6GHjFp3GECAxTEJFn8RbDtMJoLLtL8X0W030nYgIhkjVJ6xzrb_50cf_KP-E3MD35gDcU9Krliv3DKBWlT1vO88vaDwnOw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Humoral+Immunity+against+SARS-CoV-2+and+the+Impact+on+COVID-19+Pathogenesis&rft.jtitle=Molecules+and+cells&rft.au=Lee%2C+Eunjin&rft.au=Oh%2C+Ji+Eun&rft.date=2021-06-01&rft.pub=Korean+Society+for+Molecular+and+Cellular+Biology&rft.issn=1016-8478&rft.eissn=0219-1032&rft.volume=44&rft.issue=6&rft.spage=392&rft.epage=400&rft_id=info:doi/10.14348%2Fmolcells.2021.0075&rft_id=info%3Apmid%2F34059562&rft.externalDocID=PMC8245316 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1016-8478&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1016-8478&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1016-8478&client=summon |